# A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

> **NCT04772885** · PHASE1 · COMPLETED · sponsor: **Kymera Therapeutics, Inc.** · enrollment: 154 (actual)

## Conditions studied

- Healthy Volunteer
- Atopic Dermatitis
- Hidradenitis Suppurativa

## Interventions

- **DRUG:** KT-474/Placebo
- **DRUG:** KT-474

## Key facts

- **NCT ID:** NCT04772885
- **Lead sponsor:** Kymera Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-23
- **Primary completion:** 2022-10-20
- **Final completion:** 2022-10-20
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2022-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04772885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04772885, "A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04772885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*